DENGUE FEVER SPOTLIGHT & FACTS

- Dengue haemorrhagic fever (DHF), a potentially lethal complication, was first recognized in the 1950s..

- 2.5 billion people – two fifths of the world's population – are now at risk

- In 2007 alone, there were more than 890 000 reported cases of dengue in the Americas.

- The disease is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, South-east Asia and the Western Pacific

- An estimated 500 000 people with DHF require hospitalization each year...

- About 2.5% of those affected die,a very large proportion being children.

- Without proper treatment, DHF fatality rates can exceed 20%..
NEWS & ARTICLES
Arbovax Aims to Remove the Sting from Mosquito-Borne Diseases
You can't take the bite out of the mosquito, but a small Raleigh biotechnology company could become very big by taking the might out of that sometimes dead..

Arbovax, Inc. and Immunobiosciences, Inc announce a Collaborative Agreement on Dengue Vaccine Research
Arbovax, Inc (Arbovax) and Immunobiosciences, Inc (IBI) today announced that they will initiate research collaboration on the development of safe and effective ..
ABOUT US


Senior Management and Board of Directors


Malcolm Thomas, President and Chief Executive Officer
Mr. Thomas is a seasoned senior business executive with over 20 years experience in the biotechnology and biologicals markets. He has Multinational Corporation and early stage company experience at increasing levels of responsibility.

Chris English, Chairman of the Board
Chris English served as President of Biometric Imaging, a biotechnology company focusing on medical diagnostics, successfully negotiating the sale of the company to Becton Dickinson for US $85 million in 1999.  Prior to joining Biometric Imaging, as Chief Executive Officer of BioLumin, he managed the progress of this start-up development company in the fluorescence/absorbance life science research market from infancy to successful market entrance and acquisition by Molecular Dynamics. 

Jonathan Lawrie, Ph.D., Director
Dr. Lawrie was previously Founding President and CEO of StemCo Biomedical where he successfully raised $16 million in 2 rounds of venture capital financing. Before that, he was Director of Business Development at Becton Dickinson (BD) Technologies and was head of BD’s Global Biotechnology Incubation Program that supported Merix Bioscience, Norak Bioscience and SyneCor Biosciences. 

Leslie Alexandre DPH, Director
Dr. Leslie Alexandre is Director of Corporate Relations for Healthcare and Life Sciences at NC State University’s College of Management. From August 2002 through January 2007, Dr. Alexandre was President and Chief Executive Officer of the North Carolina Biotechnology Center, a state-funded private, non-profit corporation dedicated to providing long-term economic and societal benefits to North Carolina by supporting biotechnology research, business and education statewide.

Charlton Owensby MD JD MBA, Director
Dr. Charlton Owensby is a practicing physician, attorney, and investor with a keen interest in early stage companies, especially those related to healthcare, life-science, and biotechnology. He actively promotes the need for capital for these small companies and enjoys the discovery, learning, and association with these entrepreneurs as they create real value from simple ideas.


SCIENTIFIC FOUNDERS

Dennis Brown, Ph.D., Chairman of Scientific Advisory Board
Dr. Brown received a Ph.D in Molecular Biology from the University of Pennsylvania in 1967.  He has served as Assistant Professor of Biology at Dartmouth College, Associate Professor of Medical Pharmacology at the University of Maryland, Professor of Genetics at the University of Cologne (Germany), Professor of Microbiology, Director of the Cell Research Institute and Chair of the Division of Biological Sciences at the University of Texas at Austin.  He has served as Professor and Department Head of Molecular & Structural Biochemistry at North Carolina State University since 1997. 

Raquel Hernandez, Ph.D.
Dr. Hernandez received a Ph.D. in Microbiology from the University of Texas at Austin. She is Research Associate Professor of Molecular and Structural Biochemistry at North Carolina State University. Dr. Hernandez is author or co-author of 14 scientific publications.  She is an expert in the field of virus assembly and function. She is co-inventor, with Dennis Brown, of the technology that is being developed by Arbovax.


    Home    Our Technology    Development Pipeline    News & Articles    About Us    Contact Us     Dengue Fever

Arbovax.com © 2008. All rights reserved | Web Site developed by
eCaribbean Ltd